SPHK1 and colitis: Co‐administration of mesalamine and PTX produced a more pronounced effect, significantly reducing SPHK and S1P content by 48.89% (F = 582.9, p < 0.0001) and 38.01% (F = 1755, p < 0.0001), respectively, in comparison with the colitis group.